E-LIB Suche - Ergebnisse für: Richardson, Paul G.

1

Prophylactic, preemptive, and curative treatment for sinuso..:

Mohty, Mohamad ; Malard, Florent ; Abecasis, Manuel...
10.1038/s41409-019-0705-z. , 2024

Link: https://hdl.handle.net/2..

2

Clinical perspectives on the optimal use of lenalidomide pl..:

Richardson, Paul G ; Durie, Brian G ; Rosiñol, Laura...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620581/. , 2023

Link: http://www.ncbi.nlm.nih...

3

Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed..:

Dimopoulos, Meletios A ; Dytfeld, Dominik ; Grosicki, Sebastian...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870233/. , 2023

Link: http://www.ncbi.nlm.nih...

4

Heterogeneity of B cell lymphopoiesis in patients with prem..:

Jakubikova, Jana ; Cholujova, Danka ; Beke, Gabor...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977435/. , 2023

Link: http://www.ncbi.nlm.nih...

5

Pomalidomide, bortezomib, and dexamethasone at first relaps..:

Richardson, Paul G ; Schjesvold, Fredrik Hellem ; Weisel, Katja...
Richardson, Paul G. Schjesvold, Fredrik Hellem Weisel, Katja Moreau, Philippe Anderson, Larry D. White, Darrell Rodriguez-Otero, Paula Sonneveld, Pieter Engelhardt, Monika Jenner, Matthew Corso, Alessandro Dürig, Jan Pavic, Michel Salomo, Morten Beksac, Meral Oriol, Albert Lindsay, Jindriska Liberati, Anna Marina Galli, Monica Robak, Pawel Larocca, Alessandra Yagci, Munci Vural, Filiz Kanate, Abraham S. Jiang, Ruiyun Grote, Lara Peluso, Teresa Dimopoulos, Meletios . Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics. European Journal of Haematology. 2022, 108(1), 73-83. , 2022

Link: http://hdl.handle.net/10..

6

Pomalidomide, bortezomib, and dexamethasone at first relaps..:

Richardson, Paul G ; Schjesvold, Fredrik ; Weisel, Katja...
European Journal Of Haematology. , 2022

Link: https://hdl.handle.net/1..

7

Pomalidomide, bortezomib, and dexamethasone at first relaps..:

Richardson, Paul G ; Schjesvold, Fredrik ; Weisel, Katja...
European Journal Of Haematology. , 2022

Link: https://hdl.handle.net/1..

8

Lenalidomide, bortezomib and dexamethasone induction therap..:

McCaughan, Georgia J ; Gandolfi, Sara ; Moore, John J.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796722/. , 2022

Link: http://www.ncbi.nlm.nih...

9

Daratumumab plus lenalidomide/bortezomib/dexamethasone in B..:

Nooka, Ajay K ; Kaufman, Jonathan L ; Rodriguez, Cesar...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9007985/. , 2022

Link: http://www.ncbi.nlm.nih...

10

Addition of elotuzumab to lenalidomide and dexamethasone fo..:

Dimopoulos, Meletios A ; Richardson, Paul G ; Bahlis, Nizar J...
info:eu-repo/semantics/altIdentifier/pmid/35550060. , 2022

Link: https://hdl.handle.net/2..

11

Pomalidomide, bortezomib, and dexamethasone at first relaps..:

Schjesvold, Fredrik ; Richardson, Paul G ; Weisel, Katja...
European Journal Of Haematology. , 2022

Link: https://hdl.handle.net/1..

12

Risk factors for the development of orthostatic hypotension..:

Ho, Matthew ; Moscvin, Maria ; Low, Soon Khai...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9548493/. , 2022

Link: http://www.ncbi.nlm.nih...

13

Lenalidomide, bortezomib and dexamethasone induction therap..:

McCaughan, Georgia J ; Gandolfi, Sara ; Moore, John J.
10.1111/bjh.18295. , 2022

Link: http://hdl.handle.net/10..

14

Primary outcomes by 1q21+ status for isatuximab-treated pat..:

Martin, Tom ; Richardson, Paul G ; Facon, Thierry...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521209/. , 2022

Link: http://www.ncbi.nlm.nih...

15

Patient-reported outcomes in relapsed/refractory multiple m..:

Larocca, Alessandra ; Leleu, Xavier ; Touzeau, Cyrille...
British Journal of Haematology. , 2022

Link: https://ddd.uab.cat/reco..